Prelude FDA IND clearance for lead oncology program
Prelude Therapeutics reports Q4 2025 non-GAAP EPS -0.20 on revenue $6.0M, misses EPS and revenue estimates, gains FDA IND clearance for its lead oncology program
- Full-year 2025 net loss was $99.5 million, disclosed in a recent SEC filing.
- Company projects existing cash resources will fund operations into the second quarter of 2027.
- Q4 2025 non-GAAP EPS -0.20 rose 46% YoY and revenue $6.0M increased 50% YoY.
- Company confirms 2026 clinical trial starts for PRT12396, a JAK2V617F inhibitor, and PRT13722, a KAT6A degrader.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.